Baker Botts·IP / PATENT
In re Cellect and Allergan sharpen double patenting in term adjustment
A Baker Botts analysis of In re Cellect and Allergan v. MSN asks whether an obviousness-type double patenting rejection can now rest solely on the risk of a later patent term adjustment.
double-patentingpatent-term-adjustmentobviousnessfederal-circuitcellectallergan
Read the original firm alert → Saturday, October 3, 2026